ASH 2019 | Unprecedented MRD negativity in NDMM with weekly KRd-D
Ola Landgren
• 7 Dec 2019
Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results from a phase II clinical and correlative study (NCT03290950) of weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) therapy in newly diagnosed multiple myeloma (NDMM) patients. Among patients evaluable for the MRD primary endpoint, in the absence of an autologous bone marrow transplant, results show unprecedented MRD negativity rates. The promising results have prompted the development of a large randomized multicenter study (ADVANCE), evaluating wKRd-D compared with the standard of care. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
